On April 15, 2025 Flamingo Therapeutics ("Flamingo") reported that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting being held in Chicago, IL from April 25-30, 2025 (Press release, Flamingo Therapeutics, APR 15, 2025, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-poster-presentation-on-the-immune-modulatory-effects-of-danvatirsen-at-the-american-association-for-cancer-research-aacr-annual-meeting [SID1234651940]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details are as follows:
Poster Title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies"
Session Category/Title: Immunology/Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression
Session Time: 4/28/2025 9:00:00 AM – 12:00:00 PM
Location: Poster Section 38
Published Abstract Number: 2244
For more information, please visit the AACR (Free AACR Whitepaper) Annual Meeting 2025 website.